Trade Report: Today, Clovis Oncology’s (CLVS) “Neutral” Rating Reiterated at Piper Jaffray Cos.

Today, Clovis Oncology’s (CLVS) “Neutral” Rating Reiterated at Piper Jaffray Cos.

Piper Jaffray Cos. reissued their neutral rating on shares of Clovis Oncology Inc. (NASDAQ:CLVS) in a research note published on Wednesday morning. Piper Jaffray Cos. currently has a $42.00 price objective on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on CLVS. Stifel Nicolaus reiterated a buy rating and set a $30.00 target price on shares of Clovis Oncology in a research report on Thursday, June 30th. Credit Suisse Group AG reiterated a hold rating on shares of Clovis Oncology in a research report on Tuesday, July 12th. SunTrust Banks Inc. started coverage on Clovis Oncology in a research report on Friday, August 5th. They set a buy rating and a $25.00 target price on the stock. JPMorgan Chase & Co. reiterated a hold rating and set a $13.00 target price on shares of Clovis Oncology in a research report on Tuesday, August 9th. Finally, Zacks Investment Research upgraded Clovis Oncology from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Thursday, August 11th. Seven investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $36.39.

Clovis Oncology (NASDAQ:CLVS) opened at 31.85 on Wednesday. The stock’s market cap is $1.23 billion. The stock has a 50 day moving average price of $31.36 and a 200 day moving average price of $19.25. Clovis Oncology has a 52 week low of $11.57 and a 52 week high of $109.18.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.13) by $0.06. During the same period in the previous year, the company earned ($2.10) earnings per share. On average, equities analysts predict that Clovis Oncology will post ($9.25) earnings per share for the current year.

Large investors have recently bought and sold shares of the stock. Parametric Portfolio Associates LLC bought a new stake in Clovis Oncology during the second quarter worth about $144,000. Fox Run Management L.L.C. bought a new stake in Clovis Oncology during the second quarter worth about $154,000. CIBC World Markets Inc. raised its stake in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Clovis Oncology during the first quarter worth $233,000. Finally, Royal Bank of Canada raised its stake in shares of Clovis Oncology by 2,075.9% in the second quarter. Royal Bank of Canada now owns 18,212 shares of the biopharmaceutical company’s stock worth $250,000 after buying an additional 17,375 shares during the period. Institutional investors and hedge funds own 98.50% of the company’s stock.

Clovis Oncology Company Profile

Related posts

Leave a Comment